

# William Todd Penberthy, Ph. D.

1 (689) 247-0254 • [WTPENBER@GMAIL.COM](mailto:WTPENBER@GMAIL.COM) • [WWW.CMESCRIBE.COM](http://WWW.CMESCRIBE.COM)

Winter Park, Florida, USA

## SUMMARY

With a PhD in Biochemistry followed by post-doctoral training and faculty research experience, I specialize in medical and scientific writing and communications for the biomedical and pharmaceutical industries for the past 11 years (since 2012) as a self-employed principal writer.

As a researcher, I established and directed drug discovery collaborations with industry, collaborated with clinicians and researchers, directed a core facility, mentored graduate students, and trained laboratory technicians. I have also been a panel member for drug development, been an invited speaker at research hospitals and at national/international meetings, taught college- and graduate-level courses, and have been an invited journal reviewer as well as primary author of scientifically reviewed manuscripts and textbook chapters for the medical community. This experience has been invaluable to my current career as a principal medical /scientific writer, providing the background needed to gain understanding of various therapeutic areas and scientific concepts to effectively communicate with clients and to be able to present data accurately and succinctly for manuscripts, slide decks, abstracts, grants, CME, investigator brochures, and many other documents (see “Experience” below).

In addition to my 11 years of experience in the pharmaceutical industry, I have gained experience in devices over the past 4 years. For devices, I have written peer-reviewed publications, directory reports, meta-analysis, abstracts, and reviews. This includes research (background and up to date), graphics, presentation, formatting to journals, and content organization.

My therapeutic area focus has been mostly in oncology, neurology (multiple sclerosis/epilepsy), and cardiovascular disease, but includes a wide range of TA experience and I am comfortable writing about any indication.

## CAREER HISTORY

- 2012 to Current: Principal writer CMEScribe LLC
- Jan 2010-Oct 2012, Research Professor, University of Central Florida, Orlando, FL
- Dec 2004-Dec 2009, Research Professor, University of Cincinnati, Cincinnati, OH
- Aug 1999 to Nov 2003, Post-doctoral Fellow, UCLA (Los Angeles, CA) and Tufts University (Boston, MA)

## EDUCATION

- Ph. D., Biochemistry, University of Tennessee, Memphis, TN
- B.S., Biology, University of Central Florida, Orlando, FL

W. Todd Penberthy, PhD  
1(689) 247-0254  
WTPENBER@GMAIL.COM

## FORMATS

- Needs Assessments: all types of breast cancer (*funded*), desmoid tumors (*funded*), SCLC, HNCC, cervical cancer, heart failure, multiple sclerosis (*funded*), chronic kidney disease, non-invasive prenatal testing with next generation sequencing, IgA nephropathy, idiopathic hypersomnia, Huntington's disease, diabetes, systemic lupus erythematosus, pediatric multiple sclerosis, schizophrenia, insomnia disorders, generalized tonic-clonic seizures, cystic fibrosis, & more
- CME course development, faculty planning guides, CME credit grant applications, Q&A with data accumulation, slide sets (PowerPoint, Keynote)
- Peer-reviewed manuscripts, meta-analysis, and/or reviews:
- Published or submitted: *Nature Immunology*, *JAMA*, *Epilepsia*, *Journal of Managed Care Specialty Pharmacy*, *Clinical Nutrition*, *Antimicrobial Agents and Chemotherapy*, *Biomaterials*, *BMJ Open*, and *Nanomedicine*, and more
- Medical technology directory reports: Comprehensive reviews focused on cutting edge medical technologies for practice, budgetary and policy decisions. Subscription only (see <https://www.hayesinc.com/hayes/publications/medical-technology-directory/>).
- Scientific Advisor for [Aspen Laser Systems](#), 2021-; 2023 published meta-analysis & case study using high-powered 30-watt 810nm laser photobiomodulation to effectively reverse prosopagnosia and eliminate seizures in a patient; published 2022.
- Provide scientific and medical writing consulting services to clients.
- News pieces with an interview for 4 years ongoing for *BioWorld* reporting on cutting edge publications in *Science* and *Nature* family of journals especially *Science Translational Medicine*
- White papers focused on high-throughput instrumentation platform assays towards optimal, accurate, and most reliable measures of HbA1c and androstenedione.
- Systematic review with meta-analysis just published in the *Journal of Lasers in Medical Sciences*, 2022; Another meta-analysis on topic has been completed. The accepted paper identified 21 RCTs meeting inclusion criteria for involving 1064nm wavelength high-powered (>1.0W) lasers used in photobiomodulation and analysis was performed using Cohen's *d* effect size calculations as a means of quantifying efficacy for these devices.
- Textbook chapters:
  - Present Knowledge in Nutrition, Niacin and Biotin, 10<sup>th</sup> and 11<sup>th</sup> eds.; 2020 & 2012
  - Biochemical, Physiological, and Molecular Aspects of Human Nutrition, Niacin, Riboflavin, and Thiamin, 3<sup>rd</sup> and 4<sup>th</sup> eds.; 2019 & 2012
- Invited presentations: Mayo Clinic, Cleveland Clinic, panel participant (PARP1 inhibitors for glioblastoma), more...

W. Todd Penberthy, PhD  
1(689) 247-0254  
WTPENBER@GMAIL.COM

## SELECT PUBLICATIONS

- Hedaya R, Lubar J. [Reversal of Acquired Prosopagnosia Using Quantitative Electroencephalography-Guided Laser Therapy](#). *Photobiomodul Photomed Laser Surg* 2022.
- Penberthy, W. Todd and Charles Vorwaller. (2022) [Utilization of the 1064 nm Wavelength in Photobiomodulation: A Systematic Review and Meta-Analysis](#). *Journal of Lasers in Medical Sciences*.12:e86-.
- Vucic S, Kiernan MC, Menon P, Huynh W, Rynders A, Ho KS, et al. [Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression](#). *BMJ Open* 2021;11:e041479..
- Submissions: *JAMA*, *Epilepsia*, *Journal of Managed Care Specialty Pharmacy*, *Clinical Nutrition*, *Antimicrobial Agents and Chemotherapy*, *Biomaterials*, *BMJ Open*, and *Nanomedicine*, (2020-2022)
- Penberthy, W. Todd and James B. Kirkland. Niacin (2020) in Present Knowledge in Nutrition. 11<sup>th</sup> ed., Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.
- Penberthy, W. Todd, Mahrou Sadri and Janos Zemleni. Biotin (2020) in Present Knowledge in Nutrition. 11<sup>th</sup> ed., Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.
- Penberthy, W. Todd. Niacin, Riboflavin, and Thiamine (2019) in Biochemical, Physiological, and Molecular Aspects of Human Nutrition. 4<sup>th</sup> ed., Elsevier, St. Louis, Mo. Edited by Marie A. Caudill and Martha H. Stipanuk
- Penberthy, W. Todd, Soumya C. Chari, Amy Cole, Alexander Cole (2010). [Retrocyclins and Activity against HIV-1](#). *Cellular and Molecular Life Sciences* 68(13): 2231-2242.
- Penberthy, W. Todd (2009). [Nicotinic Acid-Mediated Activation of Both Membrane and Nuclear Receptors Towards Therapeutic Glucocorticoid Mimetics for Potential Treatment of Multiple Sclerosis](#); *PPAR Research* 853707-.
- Penberthy, W. Todd (guest executive editor) *Current Pharmaceutical Design*, 2009. Developed theme, coordinated authors / reviewers, and provided oversight to completion. Theme: NAD Biology in Disease.
- Penberthy, W. Todd & Tsunoda, I. (2009). [The Importance of NAD in Multiple Sclerosis](#). *Current Pharmaceutical Design*. 2009; 15(1): 64-99.
- Penberthy, W. Todd (2009). [Nicotinamide Biology and Disease](#). *Current Pharmaceutical Design*;15(1): 1-2.
- Jones KS, Alimov AP, Rilo HL, Jandacek RJ, Woollett LA, Penberthy WT. [A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development](#). *Nutr Metab (Lond)* 2008;5:23.
- Penberthy WT. [Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease](#). *Curr Drug Metab* 2007;8:245–66.